First Manhattan’s Fortress Biotech FBIO Stock Holding History

First Manhattan’s Portfolio FBIO Stock Details FBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-170	Closed	-$2.09K	–	1466
2023 Q1	$2.09K	Hold	170	–	–	﹤0.01%	1381
2022 Q4	$1.67K	Hold	170	–	–	﹤0.01%	1544
2022 Q3	$2K	Hold	170	–	–	﹤0.01%	1417
2022 Q2	$2K	Hold	170	–	–	﹤0.01%	1429
2022 Q1	$3K	Hold	170	–	–	﹤0.01%	1443
2021 Q4	$6K	Buy	+170	New	+$7.58K	﹤0.01%	1346

Other funds holding FBIO

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

PCM

Perkins Capital Management Wayzata, Minnesota $133M AUM 127.86% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SAM

Shikiar Asset Management New York $396M AUM 41.06% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Corient Private Wealth Miami, Florida $72.2B AUM 27.85% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

1WM

1900 Wealth Management San Antonio, Texas $1.8B AUM 19.39% 1-Year Est. Return

First Manhattan's FBIO Position: Q2 2023 in Review

First Manhattan sold out of Fortress Biotech (FBIO) in Q2 2023, closing a stake of 170 shares — an estimated $2.09K sold.

First Manhattan first reported a position in FBIO in Q4 2021 and held it in 6 quarters. The position peaked at $6K in Q4 2021. 48 funds tracked by Wall St. Rank hold FBIO as of Q2 2023.

First Manhattan reported no remaining Fortress Biotech position as of Q2 2023 after selling out during the quarter.
First Manhattan sold 170 Fortress Biotech shares in Q2 2023, an estimated $2.09K.
First Manhattan first reported a position in Fortress Biotech in Q4 2021 and held it in 6 quarters.
First Manhattan's Fortress Biotech position peaked at $6K in Q4 2021.
48 funds tracked by Wall St. Rank held Fortress Biotech as of Q2 2023.

Based on First Manhattan's 13F filing for Q2 2023, filed 14 Aug 2023.